Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 18/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680094 | 0.90 | PIK3R1 (0.52) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680085 | 0.89 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680080 | 0.86 | PIK3CA (0.38) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680083 | 0.82 | PIK3CA (0.52) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680073 | 0.81 | PIK3CB (0.40) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680099 | 0.79 | PIK3CA (0.42) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680076 | 0.76 | PIK3CA (0.38) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680091 | 0.76 | PIK3CA (0.41) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680104 | 0.75 | PIK3CA (0.40) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 | |
| SCHEMBL1680109 | 0.75 | PIK3CA (0.40) | PIK3CDPIK3R1PIK3CAPIK3CBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | claimed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | claimed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | claimed |
| EP-2483272-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | Xcovery Holding Company LLC (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2011041399-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | TYROGENEX, INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R1 10/4885PIK3CA 2/4885 |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3R1 10/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.